Innate Pharma S.A. (IPHA)
NASDAQ: IPHA
· Real-Time Price · USD
2.25
0.02 (0.90%)
At close: May 06, 2025, 3:58 PM
2.25
0.00%
Pre-market: May 07, 2025, 06:28 AM EDT
0.90% (1D)
| Bid | 2.13 |
| Market Cap | 188.58M |
| Revenue (ttm) | 33.79M |
| Net Income (ttm) | -34.05M |
| EPS (ttm) | -0.69 |
| PE Ratio (ttm) | -3.26 |
| Forward PE | 2.91 |
| Analyst | Buy |
| Ask | 2.28 |
| Volume | 27,506 |
| Avg. Volume (20D) | 234,653 |
| Open | 2.23 |
| Previous Close | 2.23 |
| Day's Range | 2.18 - 2.35 |
| 52-Week Range | 1.29 - 3.51 |
| Beta | 0.94 |
About IPHA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol IPHA
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for IPHA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 months ago
+20.62%
Innate Pharma shares are trading higher after the ...
Unlock content with
Pro Subscription
4 months ago
+29.25%
Innate Pharma shares are trading higher after the company announced its TELLOMAK Phase 2 trial of Lacutamab demonstrated significant symptom relief and quality of life improvements.
1 month ago · businesswire.com
Innate Pharma Reports Full Year 2024 Financial Results and Business UpdateMARSEILLE, France--(BUSINESS WIRE)-- #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the y...
